Polynovo, like CUV and NAN, is/are small (ish) health care/biotech stocks that we keep an eye on. We’ve found them far too expensive, for our tastes, particularly when every player in the sector has quite respectable growth trajectories ahead of them.
As such, it was interesting to note the below announcement. The stock has been de-rating meaningfully, for a while, and the share price trajectory would have only added to whatever pressures that were simmering away, beneath the surface, to which the statement below alludes to.
It is usually better to get out ahead of such things, rather than waiting for them to spill out into the public domain (e.g. the high profile Vocus-M2 board spat of a few years back).
I went back and dug up some of our previous comments, noting back in April ($2.96) the very high expectations (which raise the prospect of disappointment).
And that the net income expectations were similarly high. As had been widely noted in the press at the time, PNV’s ability to actually grow earnings had been a source of near perennial disappointment.
Stock now at ~$1.60.
Important Information: This document has been prepared by Aequitas Investment Partners ABN 92 644 165 266 (“Aequitas”, “our”, “we”), a Corporate Authorised Representative (no. 1284389) of C2 Financial Services, (Australian Financial Services Licensee no. 502171), and is for distribution within Australia to wholesale clients and financial advisers only.
This document is based on information available at the time of publishing, information which we believe is correct and any opinions, conclusions or forecasts are reasonably held or made as at the time of its compilation, but no warranty is made as to its accuracy, reliability or completeness. To the extent permitted by law, neither Aequitas nor any of its affiliates accept liability to any person for loss or damage arising from the use of the information herein.
Please note that past performance is not a reliable indicator of future performance.
General Advice Warning: This document has been prepared without taking into account your objectives, financial situation or needs, and therefore you should consider its appropriateness, having regard to your objectives, financial situation and needs. Before making any decision about whether to acquire a financial product, you should obtain and read the relevant Product Disclosure Statement (PDS) or Investor Directed Portfolio Service Guide (IDPS Guide) and consider talking to a financial adviser.
Taxation warning: Any taxation considerations are general and based on present taxation laws and may be subject to change. Aequitas is not a registered tax (financial) adviser under the Tax Agent Services Act 2009 and investors should seek tax advice from a registered tax agent or a registered tax (financial) adviser if they intend to rely on this information to satisfy the liabilities or obligations or claim entitlements that arise, or could arise, under a taxation law.